AstraZeneca Receives FDA Approval of Omega 3 Drug Epanova

By Pharma News - DCAT Publisher

May 9, 2014

FDA has approved AstraZeneca's Epanova (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia (triglyceride levels greater than or equal to 500 mg/dL).

Epanova is the first FDA approved prescription omega-3 in free fatty acid form, according to AstraZeneca The dosage of Epanova is 2 grams (2 capsules) or 4 grams (4 capsules), making it the first prescription omega-3 to have a dosing option as few as two capsules once a day, with or without food, according to the company.

Source: AstraZeneca